News

Dietary factors were associated with measures of glucose tolerance — how well the body processes sugar in the bloodstream — among cystic fibrosis (CF) patients in a recent report. Left uncontrolled, impaired glucose tolerance is associated with the development of CF-related diabetes, or CFRD, where blood sugar levels…

Telemedicine programs for managing cystic fibrosis (CF) were at least as effective as standard in-clinic care, according to a review study. Adhering to treatment regimens and patient satisfaction with telemedicine improved significantly across most studies examined, and most participants favored continuing with telemedicine. The review study, “…

Electronic home monitoring using a spirometry device may help improve lung function in children with cystic fibrosis (CF), according to a recent study. Specifically, a standard measure of lung function called forced expiratory volume in one second (FEV1) was found significantly improved in children who used the device, compared…

Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator of liver fibrosis — in adults with cystic fibrosis (CF), according to a recent study in the U.K. However, patients with elevated markers of liver stiffness before starting on…

The lungs of people with cystic fibrosis (CF) harbor stem cells with a distinctive proinflammatory genetic signature, a new study shows. Data indicate that the proinflammatory genetic profile of these stem cells is not affected by treatment with CFTR modulators, a class of medications that can boost the…

CFTR modulator therapy was associated with increases in fecal levels of the pancreatic elastase-1 enzyme (FE-1), reflecting improved pancreatic function, among young cystic fibrosis (CF) patients in a recent study. A small subset of patients achieved FE-1 levels high enough that they were no longer considered to have…

The Cystic Fibrosis (CF) Foundation is giving up to $9 million in additional support to advance clinical testing of ARCT-032, a messenger RNA therapy with the potential to benefit anyone with CF, regardless of their disease-causing mutation. Arcturus Therapeutics, the inhalation therapy’s developer, is using the funding…

People with cystic fibrosis (CF) in the U.S. tend to live more than a decade longer now than patients did about 20 years ago, according to a study that found deaths from CF have about halved from 1999 to 2020. “These changes were relatively slow during an earlier period…

Regular assessments of food security — a measure of whether nutritionally adequate foods are available — are linked with a lower risk of children with cystic fibrosis (CF) being underweight, a U.S. study reports. Such assessments are also associated with better body mass index (BMI; a measure of body…

ReCode Therapeutics has raised $50 million in extended series B financing, which the company plans to use to help develop RCT2100, its experimental treatment for cystic fibrosis (CF). “We are delighted with the continued high level of interest in our novel approach to the targeted delivery of genetic…